HDR Gateway logo
HDR Gateway logo

Bookmarks

The impact of systemic corticosteroids on major adverse cardiovascular events, solid-tumours and mortality in adults: a retrospective cohort study.

Safe People

Organisation name

Pharmatelligence Ltd

Organisation sector

Commercial

Applicant name(s)

Craig Currie - Chief Investigator - Pharmatelligence LimitedBenjamin Heywood - Corresponding Applicant - Pharmatelligence LimitedSara Jenkins-Jones - Collaborator - Pharmatelligence LimitedThomas Berni - Collaborator - Pharmatelligence Limited

Safe Projects

Project ID

CPRD459

Lay summary

Corticosteroids (CS) are common treatments for managing inflammation, but there are limitations to its use. Even though they are commonly used, we don’t really have a clear understanding about the association of use of the drug with the risks of major adverse cardiovascular events (MACE), solid-tumours or mortality.

Technical summary

Systemic corticosteroids (CS) are important for managing inflammation, but there are limitations to its use. Few consistent data exist describing the association of CS and risks of major adverse cardiovascular events (MACE), solid-tumours or mortality.

Latest approval date

31/03/2021

Safe Data

Dataset(s) name

HES Admitted Patient Care

ONS Death Registration Data

Patient Level Index of Multiple Deprivation

Safe Setting

Access type

Release